LifeSciVC

NOVEMBER 28, 2023

Market conditions like this are demoralizing in the worst way. Furthermore, to make matters even more complicated, that same summer, markets had already turned sour, and the sentiment was darkening by the day. The biotech equity markets had effectively shut off the idea of an IPO (which was one of several paths we had mapped out).

Marketing 91

Marketing FDA Pharma Companies Government 91

DrugBank

MARCH 7, 2024

The landscape of weight loss drugs has been rapidly evolving, and 2024 is poised to be another transformative year in this market. Pharmaceutical researchers, in particular, have a keen interest in understanding the unfolding dynamics of this market. Let’s delve into what lies ahead in the coming year.

Pharmaceutical Companies 98

Pharmaceutical Companies Clinical Trials Pharmaceuticals Therapies 98

Drug Target Review

JULY 4, 2023

These therapies have broadened treatment options for patients to expand beyond the more traditional small molecule drug alternatives. The global ADC market is expected to continue this steep upward trajectory and is anticipated to exceed $16 Billion by 2026. 3D rendering of Antibody Drug Conjugate Molecules.

Small Molecule 145

Small Molecule Drugs Clinical Pharmacology Trials 145

Antidote

JULY 29, 2022

The process of getting a new drug to market is an expensive one. billion to bring a new therapy to market. In 2019 alone, research and development spending totaled $186 billion for the global pharmaceutical industry. Between 2009 and 2018, U.S.

Clinical Trials 96

Clinical Trials Trials Therapies Pharmaceuticals 96

PPD

DECEMBER 16, 2024

Addressing these underlying factors is essential; only by tackling the complexities of recruitment, timelines and regulatory compliance can sponsors achieve cost-effective and efficient trials, paving the way for long-term success in todays demanding market. Nearly 39% of sponsors cite these costs as primarily driven by complex protocols.

Drug Development 52

Drug Development Clinical Trials Compliance Trials 52

DrugBank

OCTOBER 17, 2024

By harnessing the vast amounts of data generated throughout the development pipeline, pharmaceutical companies can accelerate the discovery of novel therapies, optimize clinical trial design, enhance drug safety monitoring, and deliver personalized medicine, ultimately improving patient outcomes and transforming the future of healthcare.

Drug Development 98

Drug Development Metabolic Stability Clinical Trials Drugs 98

DrugBank

MARCH 15, 2024

According to Grand View Research , the global weight loss and weight management market size was valued at $142.5 Many drug discovery and repurposing initiatives are shifting focus to capturing a share of this market in light of Eli Lilly and the Novo Nordisk success. With sales soaring to $2.2 for this class of drugs.  

Pharmaceutical Companies 97

Pharmaceutical Companies Pharmaceuticals Treatment Clinical Trials 97

DrugBank

AUGUST 20, 2024

If you're a pharmaceutical researcher or drug developer, understanding these breakthroughs is critical to staying at the forefront of innovation. You’ll discover real-world examples, such as the transformation of KRAS from an undruggable target to a success story in targeted therapy.

Therapies 98

Therapies Pharmaceuticals Disease Research 98

Drug Channels

APRIL 8, 2022

Michael discusses patient support challenges that are unique to specialty-lite pharmaceuticals. He goes on to describe four new categories of patient solutions and pharmacy models specific to this growing market segment.

Specialty Pharmacies 96

Specialty Pharmacies Production Pharmacy Therapies 96

Drug Target Review

DECEMBER 5, 2024

Viral vectors have been crucial in transforming the gene therapy landscape due to their natural ability to infect cells. 1 In 2017, the US Food and Drug Administration (FDA) approved the first AAV-based gene replacement therapy (Luxturna), for Leber congenital amaurosis type 2.

Therapies 52

Therapies Virus DNA Compliance 52

DrugBank

DECEMBER 18, 2024

A new shift is occurring in the pharmaceutical industry, leading to a rapidly expanding field known as digital therapeutics (DTx). DTx interventions include sensor-equipped wearable devices, remote patient monitoring tools, and virtual reality platforms integrated with conventional pharmaceutical treatments.

Pharmaceuticals 52

Pharmaceuticals Pharmaceutical Companies Treatment Therapies 52

The Pharma Data

FEBRUARY 24, 2022

Designation is supported by Phase II efficacy and safety data that will be presented at ATS 2022 Boehringer Ingelheim plans to study this novel investigational therapy in patients with progressive fibrosing interstitial lung diseases. senior vice president, Medicine and Regulatory Affairs, Boehringer Ingelheim Pharmaceuticals, Inc. “BI

Therapies 52

Therapies FDA Clinical Trials Disease 52

DrugBank

SEPTEMBER 26, 2024

Due to the less extensive clinical trial requirements and the competitive nature of the biosimilar market, these biologics can be produced and marketed at significantly lower prices than their reference counterparts. Still, significant differences exist between these two major markets.

Biosimilars 98

Biosimilars Clinical Trials Production FDA 98

Drug Patent Watch

JANUARY 9, 2025

Enter the Contract Development and Manufacturing Organization (CDMO) a lifeline for many startups looking to bring their innovative therapies to market. The pharmaceutical landscape is evolving rapidly, with small and medium-sized biotech companies increasingly taking center stage in innovation.

Compliance 52

Compliance Drug Development Therapies Pharma Companies 52

Common Sense for Drug Policy Blog

JUNE 6, 2024

The Market for Image and Performance Enhancing Drugs (IPEDs) "The market for image and performance enhancing drugs has undergone seismic changes in the last two decades and, as has been alluded to above, its partial digitisation has created something of a dual space of commerce (Gibbs, Forthcoming ). 2014 ; Begley et al.

Marketing 40

Marketing Drugs Production Pharmaceuticals 40

Drug Channels

JULY 11, 2022

President and CEO, National Pharmaceutical Council Julie Ritchie Wagner, Senior Assistant General Counsel, Head of Global Ethics, Compliance, and Enforcement Legal Policy, PhRMA Joel White, Founder and President, Horizon Government Affairs Charlene Keller Fullmer, Assistant U.S. O’Brien, Pharm.

Specialty Pharmacies 98

Specialty Pharmacies Pharmacy Biosimilars Compliance 98

The Premier Consulting Blog

NOVEMBER 6, 2024

From ensuring API compatibility and advanced analytical methods to navigating device-drug interactions and post-market surveillance, developers must stay abreast of changing regulatory requirements across different regions. However, these products present unique challenges from a Chemistry, Manufacturing, and Controls (CMC) standpoint.

Production 52

Production FDA Compliance Disease 52

The Pharma Data

NOVEMBER 1, 2020

Corlieve’s lead program employs a novel AAV gene therapy approach for the treatment of refractory temporal lobe epilepsy (TLE), the most commonly diagnosed focal epilepsy in humans. Maryland , US), a leading gene therapy company. Maryland , US), a leading gene therapy company. PARIS , Nov.

Therapies 52

Therapies Science Treatment Disease 52

Alta Sciences

NOVEMBER 13, 2024

For three decades now, Altasciences has taken pride in evolving their solutions to meet the needs of pharmaceutical and biotechnology companies of all sizes, including the expansion of their labs in Seattle, WA, Columbia, MO, and Laval, Quebec. View the fascinating video series here.

Clinical Pharmacology 40

Clinical Pharmacology Laboratories Drug Development Pharmaceuticals 40

Conversations in Drug Development Trends

APRIL 4, 2024

Developing pharmaceuticals is a complex process, requiring stringent bioanalytical method validation guidelines to ensure drug safety and efficacy. To help integrate these various regulatory standards, the International Council for Harmonization (ICH) of Technical Requirements for Pharmaceuticals for Human Use was founded in 2016.

Small Molecule 80

Small Molecule Clinical Trials Pharmaceuticals Pharmaceutical Companies 80

The Pharma Data

DECEMBER 3, 2020

BioCryst Pharmaceuticals, Inc. In the long-term APeX-S trial, those who completed 48 weeks of therapy had an average attack rate of 0.8 ORLADEYO is the first and only oral therapy that was designed to prevent attacks of HAE in adults and pediatric patients age 12 and older. announced on Thursday that the U.S. attacks per month.

FDA Approval 52

FDA Approval Therapies FDA Trials 52

The Pharma Data

NOVEMBER 18, 2020

Hal came to the pharmaceutical business at mid-career, age 39. This work took him to some 50 countries and allowed Hal to meet pharmaceutical business leaders. As in all Marquis Who’s Who biographical volumes, individuals profiled are selected on the basis of reference value.

Pharmaceuticals 52

Pharmaceuticals International Engineering Government 52

The Pharma Data

JANUARY 3, 2021

03, 2021 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that Ocumension Therapeutics, a China-based ophthalmic pharmaceutical company traded on the Stock Exchange of Hong Kong (1477.HK),

Pharmaceuticals 52

Pharmaceuticals Pharmaceutical Companies Licensing Licensing 52

Drug Target Review

OCTOBER 31, 2023

Ashley Hall, CDO of Reneo Pharmaceuticals Throughout my education I was discouraged by many around me. How did that transfer into the pharmaceutical industry? This sector of the pharmaceutical industry combined both my science and law background. I’ve been lucky to have seen several drugs make it all the way to market.

Cell Biology 107

Cell Biology Pharmaceuticals Science Disease 107

DrugBank

JUNE 27, 2024

Currently, about one-third of recent drug approvals and 25% of the pharmaceutical industry's annual revenue is coming from repurposed drugs.This trend is being championed industry-wide, by public organizations and nonprofits, with numerous small companies diving in and academic publications on the subject showing great popularity.

Drugs 98

Drugs Pharma Companies Clinical Trials Computational Chemistry 98

Conversations in Drug Development Trends

DECEMBER 7, 2023

Moreover, these delays impact getting potentially lifesaving therapies to patients in need. We are acutely aware that turnover in key project team personnel can lengthen project timelines and inflate clinical trial costs.

Clinical Trials 136

Clinical Trials Clinical Development Trials Pharmaceutical Companies 136

The Pharma Data

MARCH 29, 2022

Boehringer Ingelheim and Veeva Systems (NYSE: VEEV) today announce Boehringer Ingelheim’s selection of Veeva Development Cloud to drive end-to-end processes and seamless information sharing enterprise wide for greater speed in the delivery of innovative therapies. About Boehringer Ingelheim. Source link: [link].

Therapies 52

Therapies Clinical Development Pharmaceutical Companies Research 52

LifeSciVC

OCTOBER 13, 2022

This summer, approvals on both sides of the Atlantic – for beta thalassemia and cerebral adrenoleukodystrophy in the United States and for severe hemophilia A and aromatic L-amino acid carboxylase deficiency in Europe – show that regulators are likely open to green-lighting a range of emerging gene therapies.

Therapies 40

Therapies Disease Treatment Marketing 40

PPD

OCTOBER 8, 2024

PPD FSP solutions embrace the biotech mindset As a longtime provider to all types of pharmaceutical and medical device developers around the world, we know that our clients in biotech are not the same as those in any other sector of the industry. Augment your existing services with PPD FSP solutions.

Trials 98

Trials Clinical Trials Clinical Development Clinical Research 98

The Pharma Data

JANUARY 27, 2021

28, 2021 /PRNewswire/ — CASI Pharmaceuticals (Formerly Known As EntreMed, Inc.). A total of 15 patients have been recruited to date in the Phase I dose escalation part of the study, all of whom were late stage and have failed conventional treatments, including several lines of rituximab-containing therapies.

Pharmaceuticals 52

Pharmaceuticals Clinical Trials Licensing Licensing 52

Agency IQ

JUNE 9, 2023

What will the orphan drug market exclusivity haircut mean for industry? Just over a month ago, the European Commission released its proposal for the new pharmaceutical directive and regulation. provides a 10-year market exclusivity period. High-priced cell and gene therapies are being increasingly developed for rare diseases.

Marketing 40

Marketing Regulations Biosimilars Drugs 40

Drug Target Review

MARCH 3, 2025

In this interview, Professor Schwamborn discusses his research, the promise of brain organoids, and his vision for the future of stem cell-based therapies. However, promising pilot data from ongoing collaborations with pharmaceutical companies suggest that brain organoids are set to become a valuable tool in preclinical research.

Disease 52

Disease Treatment Therapies Cell Biology 52

The Pharma Data

JANUARY 10, 2021

Dr. Ken Kobayashi, CMO, ASLAN Pharmaceuticals, commented: “The emerging safety profile of ASLAN004 has allowed us to move directly into the expansion cohort at the highest dose, 600mg weekly, based on blinded safety data, accelerating the completion of the study. SINGAPORE, Jan. Media and IR contacts. Forward looking statements.

Clinical Trials 52

Clinical Trials Pharmaceuticals Trials Treatment 52

Drug Channels

MAY 9, 2022

Emily Phillips, Reimbursement, Patient Advocate, & Government Affairs Leader Melissa Beatty, Director, Patient Services and Reimbursement, CTI Bio Pharma Chad Bower, Executive Director, Field Reimbursement & Oncology Solutions, US Market Access, Daiichi Sankyo, Inc. Cortes, Executive Assistant U.S. Attorney, U.S.

Specialty Pharmacies 75

Specialty Pharmacies Pharmacy Pharmaceuticals Government 75

The Pharma Data

OCTOBER 21, 2020

In the midst of the global pandemic, the analysis found no antiretroviral therapy interruptions across the entirety of the ongoing clinical development programme for long-acting cabotegravir and rilpivirine. Of those participants who transitioned back to injectables, the median duration of oral therapy was 51 days.

Clinical Development 52

Clinical Development Therapies Clinical Trials Treatment 52

The Pharma Data

NOVEMBER 10, 2020

–( BUSINESS WIRE )– Mirum Pharmaceuticals, Inc. About Mirum Pharmaceuticals. Mirum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. 11, 2020 00:00 UTC.

Pharmaceuticals 40

Pharmaceuticals Therapies Treatment Disease 40

Drug Patent Watch

FEBRUARY 26, 2025

Unlocking the Secrets to Patenting Drug Combinations: Strategies and Challenges As a pharmaceutical professional, you know how crucial it is to stay ahead of the curve when it comes to patenting innovative treatments. But, have you ever wondered what it takes to successfully patent these complex combinations?

Drugs 40

Drugs Production Regulations Therapies 40